Search Results
Showing 4 of 4 search results for:
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Status
Condition
Small Cell Lung Carcinoma
Phase
INTERVENTION
Drug: CC-90011, Drug: Cisplatin, Drug: Carboplatin, Drug: Etoposide, Drug: Nivolumab
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 1 of 4
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Status
Condition
Neoplasms
Phase
INTERVENTION
Drug: CC-90011, Drug: Nivolumab
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 2 of 4
A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Status
Condition
Neoplasms, Lymphoma, Non-Hodgkin
Phase
INTERVENTION
Drug: CC-90011
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 3 of 4
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : Male
Accepts Healthy Volunteers :
Result 4 of 4